A study to assess the schemas of retreatment with Lutathera in patients with new progression of intestinal well-differentiated neuroendocrine tumor.

ABSTRACT: Primary objectives: To evaluate the efficacy of two additional cycles of Lutathera (one injection every two months), compared to active surveillance during 6 months in patients already retreated with two cycles. Primary endpoints: Disease Control Rate at 6 months from randomization (defined as Complete Response, Partial Response and Stable Disease from RECIST v1.1) with an evaluation every 2 months.

DISEASE(S): Neuroendocrine Tumor,Patients Présentant Une Nouvelle Progression De Leur Tumeur Neuroendocrine Intestinale Bien Différenciée,Patients With New Progression Of Intestinal Well-differentiated Neuroendocrine Tumor.

PROVIDER: 2541272 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR